258 related articles for article (PubMed ID: 33512754)
1. Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
He Y; Pachori A; Chen P; Ma S; Mendonza AE; Amer A; Marbury TC; Hinder M
Diabetes Obes Metab; 2021 May; 23(5):1182-1190. PubMed ID: 33512754
[TBL] [Abstract][Full Text] [Related]
2. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
He YL; Haynes W; Meyers CD; Amer A; Zhang Y; Mahling P; Mendonza AE; Ma S; Chutkow W; Bachman E
Diabetes Obes Metab; 2019 Jun; 21(6):1311-1321. PubMed ID: 30724002
[TBL] [Abstract][Full Text] [Related]
3. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
de Boer RA; Núñez J; Kozlovski P; Wang Y; Proot P; Keefe D
Br J Clin Pharmacol; 2020 Jul; 86(7):1346-1356. PubMed ID: 32068914
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Yokote K; Sano M; Tsumiyama I; Keefe D
Diabetes Obes Metab; 2020 Jul; 22(7):1102-1110. PubMed ID: 32072763
[TBL] [Abstract][Full Text] [Related]
5. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Bays HE; Kozlovski P; Shao Q; Proot P; Keefe D
Obesity (Silver Spring); 2020 May; 28(5):870-881. PubMed ID: 32187881
[TBL] [Abstract][Full Text] [Related]
6. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
Weir MR; McCullough PA; Buse JB; Anderson J
Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
[TBL] [Abstract][Full Text] [Related]
7. Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.
Tan S; Ignatenko S; Wagner F; Dokras A; Seufert J; Zwanziger D; Dunschen K; Zakaria M; Huseinovic N; Basson CT; Mahling P; Fuhrer D; Hinder M
Diabetes Obes Metab; 2021 Nov; 23(11):2595-2599. PubMed ID: 34263971
[TBL] [Abstract][Full Text] [Related]
8. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
9. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
12. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
Weir MR; Kline I; Xie J; Edwards R; Usiskin K
Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
[TBL] [Abstract][Full Text] [Related]
13. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
14. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
Harrison SA; Manghi FP; Smith WB; Alpenidze D; Aizenberg D; Klarenbeek N; Chen CY; Zuckerman E; Ravussin E; Charatcharoenwitthaya P; Cheng PN; Katchman H; Klein S; Ben-Ari Z; Mendonza AE; Zhang Y; Martic M; Ma S; Kao S; Tanner S; Pachori A; Badman MK; He Y; Ukomadu C; Sicard E
Nat Med; 2022 Jul; 28(7):1432-1438. PubMed ID: 35725922
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
PLoS One; 2014; 9(8):e105638. PubMed ID: 25166023
[TBL] [Abstract][Full Text] [Related]
16. Renal effects of canagliflozin in type 2 diabetes mellitus.
Perkovic V; Jardine M; Vijapurkar U; Meininger G
Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans.
Wang-Lakshman L; Mendonza AE; Huber R; Walles M; He Y; Jarugula V
Xenobiotica; 2021 Apr; 51(4):413-426. PubMed ID: 33413022
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
19. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Wheeler DC; Toto RD; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Pecoits-Filho R; Correa-Rotter R; Rossing P; Sjöström CD; Umanath K; Langkilde AM; Heerspink HJL;
Kidney Int; 2021 Jul; 100(1):215-224. PubMed ID: 33878338
[TBL] [Abstract][Full Text] [Related]
20. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
